NEW DISCOVERY: Supplementation with a newly discovered substance in the body can extend the remaining life expectancy by 23 times.
With the rapid development of biomedical research, many scenarios that were once considered science fiction are becoming reality. The world's second pig heart transplant was a miracle when Faucette, a 58-year-old American veteran, successfully underwent a pig heart transplant and was able to sit in a chair and laugh less than two days after the operation. On the other hand, a universal cancer vaccine capable of killing 70% of cancer cell types has officially entered the clinical trial stage, bringing new hope to cancer**. And the ability of paralyzed patients from the neck down to walk freely after being implanted with a microchip, and even climb three flights of stairs, these cutting-edge technologies are rapidly disrupting our lives.
However, with the continuous development of medical research,"How to fight aging"It is becoming a hot topic in cutting-edge medical research. Recently, the journal Cell published a subversive research result, a team from Professor Shinichiro Imai from the University of Washington School of Medicine in the United States injected a newly discovered enzyme ENAMPT (extracellular nicotinamide phosphoribosyltransferase) into elderly mice, extending the lifespan of mice that originally had only 2 months of life to 46 months, extended by 23 times as much. What's even more surprising is that the appearance and fur of these mice have undergone a noticeable change in youthfulness.
The team also found that Enampt is also present in the human body, where it works to synthesize a coenzyme called NAD+, which is responsible for DNA repair and 95% of energy metabolism. As we age, the level of ENAMPT in the human body decreases, resulting in a decrease in NAD+ synthesis, an accelerated aging rate, a decrease in immunity, memory loss, a decrease in exercise ability, cognitive function and other aging-related problems.
This study from the University of Washington provides a strong theoretical basis for intervening in aging with the help of NAD+ boosting, and has also become the core mechanism of aging inhibition products such as Schginer. Hundreds of articles published in top journals such as Nature and Science** have confirmed the potential of NAD+ to boost aging and increase longevity in a variety of animal models.
This experiment also confirmed that by supplementing Enampt to enhance NAD+ synthesis ability, physical activity, sleep quality, learning ability, memory ability, retinal cell and nerve function in elderly mice were reversed at a younger age. This groundbreaking study from the University of Washington School of Medicine reveals an alternative to aging interventions such as Schginer's approach to boosting NAD+ to reverse aging-induced decline and prolong lifespan. If all goes well, this new breakthrough is expected to enter human clinical trials within the next 10 years, and its effects may exceed those currently available.
Since 2013, when David Sinclair's team at Harvard Medical School first recognized the potential of enhancing NAD+ to slow aging and prolong life, this field has become the focus of academic and biomedical fields. Various biopharmaceutical companies are also competing to develop related technologies, but due to the high technical threshold, early NAD+ technology achievements are expensive. However, with the advent of products such as Schginer, the cost of NAD+ technology has dropped dramatically and has become more affordable.
The listing of Schginer has promoted the research progress of Harvard's NAD+ enhancement technology. Recently, Keio University in Japan confirmed that this technology can even regain the ability of differentiation and restore cell viability of inactivated senescent stem cells. A team of researchers from the University of Oklahoma in the United States has also found that this technology has the potential to improve the neurological decline associated with aging.
Backed by these exciting findings, Schginer has become popular among high-net-worth individuals worldwide. Bank of America Merrill Lynch**, biomedical technology related to life extension has become a market of more than $400 billion and is becoming a hot spot for future capital competition. In 2023, JD.com also smelled a business opportunity and introduced Shijiner to China, gaining the attention of tens of thousands of users in a short period of time.
Demographer Samuel Preston once predicted that the key to increasing life expectancy was technological innovation in the biomedical field. The world's wealthy are investing to make this happen. One of the richest people even said he would be willing to pay $100 billion if he could get an extra 30 years of youth. This also confirms the words of Apple founder Steve Jobs before his death: no one wants to die, even those who long to go to heaven want to live longer. We are in an era of medical revolution, and the future is full of endless possibilities.